The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any r ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/regenxbio-inc-lawsuit-s ...

Group 1 - The Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026 [1] - Investors who purchased REGENXBIO securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5] - Defendants made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing material adverse facts about the trial's efficacy and safety [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading statements [5] Group 3 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between February 9, 2022, and January 27, 2026, and aims to provide compensation to investors without any out-of-pocket fees through a contingency fee arrangement [2]. - Investors wishing to serve as lead plaintiffs must file their motion by April 14, 2026, to represent other class members in the litigation [1][3]. Group 2: Case Background - The lawsuit claims that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I (Hurler syndrome) [5]. - Defendants allegedly made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing material adverse facts about the trial's efficacy and safety [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4].

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026. SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be enti ...

Core Viewpoint - REGENXBIO Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the safety and efficacy of its RGX-111 product candidate, which led to a clinical hold by the FDA after a participant developed a tumor [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from February 9, 2022, to January 27, 2026, with a deadline for lead plaintiff appointments set for April 14, 2026 [1]. - The complaint alleges that REGENXBIO consistently made positive statements about RGX-111 while concealing adverse safety and efficacy information from investors [1]. Group 2: Impact on Shareholders - Shareholders who purchased RGNX shares during the class period are encouraged to contact the DJS Law Group regarding potential recovery of losses [1]. - The lawsuit highlights the potential financial impact on shareholders due to the misleading public statements made by the company [1].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities during the specified Class Period, indicating potential legal claims against the company for misleading information regarding its product candidate RGX-111 [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [1][3]. Group 2: Allegations Against REGENXBIO - The lawsuit claims that REGENXBIO provided misleading information about the efficacy and safety of RGX-111, a gene therapy for Hurler syndrome, while presenting overly positive assertions about its trial success [5]. - Defendants allegedly concealed material adverse facts regarding the RGX-111 trial, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. related to a federal securities class action due to alleged violations of federal securities laws [1] - The complaint alleges that REGENXBIO and its executives made false or misleading statements and failed to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study [1] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy for MPS I after a case of neoplasm was reported in a participant [1] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the clinical studies [1] - Following the FDA's announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share [1] Group 2 - The deadline for investors to seek the role of lead plaintiff in the class action is April 14, 2026 [1] - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi encourages individuals with information regarding REGENXBIO's conduct to contact the firm, including whistleblowers and former employees [1]

The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery ...

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/regenxbio-inc-loss-submission-form/?id=183597&from=3  CLASS PERIOD: February 9, 202 ...